Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Sorafenib (Primary) ; Ritonavir
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer HealthCare
- 31 Aug 2018 Biomarkers information updated
- 01 May 2017 According to results published in the Oncologist Journal, patients were accrued between January 2006 and February 2012.
- 15 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.